Date: 2011-01-06
Type of information: Licensing agreement
Compound: antibody drug conjugates (ADCs) as potential anticancer agents
Company: Spirogen (UK) - Genentech a member of the Roche Group (USA-Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
licensing
Action mechanism:
Disease: cancer
Details: Spirogen has announced a multi-year research collaboration and license agreement with Genentech, a member of the Roche Group. The two companies will collaborate on the discovery and development of antibody drug conjugates (ADCs) as potential anticancer agents, using Spirogen's proprietary PBD drugs and associated linker technology.
Under the terms of the agreement, Spirogen will be primarily responsible for synthesizing and manufacturing drug reagents, while Genentech will use Spirogen's drug reagents to generate ADCs and evaluate their potential therapeutic utility. Genentech will have the exclusive license to fully develop and commercialize licensed products that contain these ADCs.
Financial terms: Terms of the multi-year collaboration include an initial one-off license fee, development milestones on reaching pre-defined targets and further milestones and royalties for licensed products.
Latest news:
